A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic
Reduced Gastrointestinal Complaints and Improved Quality of Life in Lung Transplant Recipients Converted From Mycophenolate Mofetil (MMF) to Myfortic (Enteric-coated Mycophenolate Sodium, Ec-mps)
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Subjects administered MMF as part of their immunosuppression regimen after lung transplantation have a high incidence of GI symptoms related to the known side-effects of this drug. Previous studies have shown that GI symptoms are an important predictor of health related quality of life in other solid organ transplants (1). GI complications are common after lung transplant (2). We hypothesize that lung transplant patients converted from MMF to Myfortic will have significant reduction in severity of GI complaints. We also hypothesize that improvement in the severity of GI complaints will lead to an improved quality of life in these subjects. The study also includes data to evaluate the effect of GI complaints on health related quality of life.
Patients will complete questionnaires at each visit. Calls from the patients to the lung transplant center with GI complaints will be queried and documented on the case report form by the research nurse at each study visit. Similarly, hospital admissions for GI related complaints in the cohort will be documented. Symptom severity and health related quality of life will be assessed through the following questionnaires that have previously been validated in populations other than lung transplant (1). These questionnaires are selected specifically to capture the impact of GI complaints as related to the health related quality of life. The questionnaires that will be completed by the patient:
i.Gastrointestinal Quality of Life Index (GIQLI)
• The GIQLI is a 36-item questionnaire that assess the impact of GI distress on daily life
ii.SF-36 Health Survey • "The SF-36 Health Survey is a questionnaire that capture practical, reliable, and valid information about functional health and well-being from the patients' point of view" (4)
iii.EQ-5D Health Questionnaire
• "The EQ-5D is a standardized instrument for use as a measure of health outcome. The EQ-5D provides a simple descriptive profile and a single value for health status" (5)
Patients will complete the three questionnaires at 4 outpatient visits occurring:
- when the patient comes in to an outpatient clinic visit after initial hospital discharge after lung transplantation with complaints of GI distress (Day 1-Convert to Myfortic);
- 60 Days;
- 90 days;
- 180 days
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232-4753
- Vanderbilt University Medical Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Ability and willingness to provide written informed consent and adhere to study regimen
- Recipients who are 18-70 years of age
- Patients who have undergone either single or double lung transplant are discharged on the standard MMF (no generic MMF will be used) therapy and complain of GI symptoms, thought to be related to their immunosuppressive regimen
Exclusion Criteria:
- Patients who have GI complaints thought to be due to factors other than immunosuppressive regimen
- Patients receiving steroid treatment for acute rejection
- Women of childbearing potential who do not agree to use at least two acceptable forms of contraception prior to starting study drug, while taking study drug, and for 6 weeks after stopping study drug
- Women who have a positive serum or urine pregnancy test at visit 1 and/or continuing through the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
다른: Patients taking Myfortic
Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Gastrointestinal Quality of Life Index (GIQLI), Baseline to 60 days:
기간: Change from Baseline to 60 days
|
Change in GIQLI after conversion from MMF to Myfortic
|
Change from Baseline to 60 days
|
|
Change in SF-36 Health Survey, Baseline to 60 days
기간: Change from Baseline to 60 days
|
Change in SF-36 Health Survey after conversion from MMF to Myfortic
|
Change from Baseline to 60 days
|
|
Change in EQ-5D Health Questionnaire, Baseline to 90 days
기간: Change from Baseline to 60 days
|
Change in EQ-5D Health Questionnaire after conversion from MMF to Myfortic
|
Change from Baseline to 60 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Gastrointestinal Quality of Life Index (GIQLI)
기간: Day 90 and Day 180
|
Change in GIQLI after conversion from MMF to Myfortic
|
Day 90 and Day 180
|
|
SF-36 Health Survey
기간: Day 90 and Day 180
|
Change in SF-36 Health Survey after conversion from MMF to Myfortic
|
Day 90 and Day 180
|
|
EQ-5D Health Questionnaire
기간: Day 90 and Day 180
|
Change in EQ-5D Health Questionnaire after conversion from MMF to Myfortic
|
Day 90 and Day 180
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Eric Lambright, MD, Vanderbilt University Medcial Center
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- Myfortic 091423
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .